Introduction
Intraductal oncocytic papillary neoplasm (IOPN) of the pancreas is an epithelial neoplasm characterized by architecturally complex and distinctive papillary projections lined by oncocytic cells [1] . In the current (2010) WHO classification, this neoplasm has been classified under the general category of intraductal papillary mucinous neoplasm (IPMN) [2] . Both
IOPNs and IPMNs present with a similar clinical picture of a cystic pancreatic lesion due to dilation of the native ducts by an intraductal neoplasm [1, 3, 4] . Also, most IOPNs and IPMNs are not associated with an invasive carcinoma component, and even cases with an invasive component have an indolent clinical course, relative to conventional pancreatic ductal adenocarcinoma (DA) [1, [3] [4] [5] [6] .
Histologically, however, IOPNs have distinctive features not found in other types of IPMNs. Unlike the mucin-filled columnar cells of IPMNs, the cells lining the papillae and ducts of IOPNs are distended by voluminous granular, oncocytic cytoplasm, and they have large round nuclei with prominent eccentric nucleoli [1, 3, 4, 7] . These cells also often have intracellular lumina that give the projections a cribriform pattern of growth [1] .
Because of the abundant mucin production in IPMNs, the pattern of expression of apomucins MUC1, MUC2, MUC5AC, and MUC6 has been used to help subclassify IPMNs [1, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Recently, many of the genetic alterations that occur in pancreatic DAs have also been studied in IPMNs. Activating point mutations in the KRAS2 oncogene are the most common and have been detected in the majority of IPMNs [19] [20] [21] [22] [23] [24] . Mutations in the tumor suppressor genes TP53 and p16/CDKN2A have also been shown to occur commonly in IPMNs [12, [19] [20] [21] [25] [26] [27] although mostly in regions of high-grade dysplasia. In contrast, SMAD4 loss, which appears to be a late event in the genetic progression of DA, is essentially limited to invasive carcinomas [12, 19, [27] [28] [29] [30] [31] . In addition, activating mutations in GNAS [22, 27, [32] [33] [34] and inactivating mutations in RNF43 [22, 27, 35] have been identified in at least half of IPMNs, especially intestinal type, and are relatively specific for the BIPMN pathway^ [22, 33] . Less common alterations involve PIK3CA, SMAD4, BRAF, CTNNB1/β-catenin, IDH1, STK11, PTEN, ATM, CDH1, FGFR3, and SRC genes [19, 27, 29, 36] .
Several other studies have investigated mucin expression and selected gene mutations in IOPNs and showed that IOPNs generally do not have specific patterns of mucin protein expression (except for MUC6 [18] ), and they do not harbor the same genetic alterations commonly seen in DAs and IPMNs [14, 22, 33, [37] [38] [39] [40] . For example, in their analysis of a single IOPN, Patel et al. did not detect mutations at codons 12 and 13 of the KRAS gene [37] . In contrast, Xiao et al. identified mutations in codon 12 of the KRAS gene in 3 of 18 (17 %) IOPNs. However, the authors acknowledged that they included IOPNs exhibiting heterogeneous epithelium [38] . Therefore, it is quite possible that the three cases they reported as KRAS mutated may have exhibited heterogeneity in differentiation and that the oncocytic features were a morphologic variation within a non-oncocytic IPMN. Also, Dal Molin et al. reported that 12 of 12 (100 %) intestinal type, 5 of 7 (71 %) pancreatobiliary type, and 27 of 53 (51 %) gastric-type IPMNs harbored a codon 201 GNAS mutation, while 2 of 2 (100 %) IOPNs in their series were found to be GNAS wild type [33] . Similarly, in a recent study investigating 11 IOPNs by targeted next-generation sequencing for a panel of 300 key cancer-associated genes, our group has confirmed that IOPNs are genetically distinct: None of our typical IOPNs revealed KRAS or GNAS mutations, and only one had RNF43, PIK3R1, and PIK3R3 mutations. Instead, ARHGAP26, ASXL1, EPHA8, and ERBB4 genes were mutated in more than one IOPN [40] .
The aim of the current study is to determine expression profile of antibodies associated with genetic alterations previously described for DAs and IPMNs (SMAD4, β-catenin, p53, mesothelin, claudin-4) as well as antibodies to mucins and differentiation markers [MUC1, MUC2, MUC5AC, MUC6, CDX2, hepatocyte paraffin-1 (HepPar-1)] in IOPNs and IPMNs to further assess the similarities/differences between these tumor types.
Materials and methods
With approval of the institutional review boards, 24 IOPNs and 22 IPMNs were retrieved from the files of the Departments of Pathology at Memorial Sloan Kettering Cancer Center, NY, NY; Johns Hopkins Hospital, Baltimore, MD; and Wayne State University, Detroit, MI. All IOPNs accessioned between the years of 1987-2003 were collected, whereas the representative IPMN cases for comparison were chosen to reflect the spectrum of grades and lines of differentiation encountered in these neoplasms. All slides of each case were re-reviewed, and the diagnoses were confirmed by the authors. All IOPNs were composed of the characteristic oncocytic cells and displayed the typical architectural features. The IPMNs were classified into three groups based on the histological lines of differentiation as defined in previous studies [10, 15, 17, 41] . IPMNs with long straight papillae with minimal branching lined by columnar cells with pseudostratified cigar-shaped nuclei like those of intestinal villous adenomas were classified as intestinal type. Those with more complex branching papillae lined by cuboidal cells with round nuclei similar to those seen in papillary neoplasms of the biliary tract were designated as pancreatobiliary type. IPMNs with papillae lined by cuboidal to tall cells with basally located nuclei and abundant apical mucinous cytoplasm resembling gastric foveolar epithelium were designated as gastric type. Only the IPMNs with a singular subtype were included. The dysplasia in the intraductal components of the neoplasms was graded as low or high based on the most severely dysplastic regions identified within the tumor [42] .
Immunohistochemistry
Using the standard avidin-biotin peroxidase method, representative formalin-fixed paraffin-embedded tissue sections of the cases were immunolabeled with markers associated with genetic alterations previously described for DAs and IPMNs (SMAD4, β-catenin, p53, mesothelin, and claudin-4) as well as mucins (MUC1, MUC2, MUC5AC, MUC6) and differentiation markers (CDX2, HepPar-1). The primary antisera and their dilutions and specificities are listed in Table 1 . After deparaffinization and blocking of endogenous peroxidase, tissue sections were steamed in citric acid (pH 6.0) or EDTA (pH 8.0) at 97°C for 30 min. Antibodies were incubated with the tissue sections for 60 to 90 min. Biotinylated anti-mouse and avidin-biotin complex were applied for 10 min each. After color development with diaminobenzadine, sections were counterstained with hematoxylin. The controls used are as follows: benign and neoplastic pancreatic tissue for SMAD4 and β-catenin, colonic adenocarcinoma for p53, neoplastic ovarian tissue for mesothelin, benign and neoplastic colon tissue for MUC2 and CDX2, benign gastric mucosa for MUC5AC and MUC6, and benign liver for HepPar-1.
For all antibodies, labeling in more than 10 % of cells was considered to be an expression. For p53 and CDX2, only nuclear labeling was regarded as expression. For SMAD4, loss of labeling was regarded to be abnormal, and for β-catenin, an alteration from the normal cell membrane pattern to nuclear labeling was considered abnormal.
Statistical analysis
Pearson χ 2 test was used for comparison of expression of antibodies in IOPNs and IPMNs. For all analyses, the IBM-SPSS version 20.0 was used, and the statistical significance was set at P < 0.05.
Results

Clinical findings
The clinical features of the 24 IOPN cases analyzed are presented in Table 2 . For the cases with available clinical information, the mean age of the patients was 68 years (range, 42 to 77). Thirteen patients were men, and nine patients were women.
Microscopic findings
IOPNs (n = 24)
Pancreatic IOPNs produced gross multilocular or rarely unilocular cysts containing papillary growths. Microscopically, the cyst walls consisted of fibrotic stroma containing inflammatory cells and atrophic acini and islets. The multilocular appearance represented multiple cystically dilated ducts or sections through multiple ductules containing tumor. The unilocular cysts likely represented a large duct distended by the neoplasm. The complexity of the papillary projections varied. The vast majority of the cases showed arborizing papillae, early coalescence of papillae, and a cribriform pattern (Fig. 1a) . These papillae were lined by multiple layers of cells with nuclear atypia. Only one case was non-papillary with a flat cyst lining of oncocytic epithelial cells.
The cytologic appearance of the cells was similar in all IOPNs, with voluminous finely granular, eosinophilic cytoplasm and large round nuclei with fine chromatin and prominent nucleoli. In the more complex papillae, intraepithelial mucincontaining lumina gave rise to the cribriform pattern mentioned above (Fig. 1b) . Scattered goblet cells were also identified.
An invasive carcinoma was detected in 8 of the 24 IOPNs. Five cases had an associated microinvasive carcinoma with invasion into surrounding stroma only. Three cases had more widespread invasion with extension into peripancreatic soft tissue and lymph node metastases. In five cases, the invasive carcinoma was characterized by small tubular units lined by oncocytic cells, cytologically similar to the intraductal component, or individual oncocytic cells within the stroma (Fig. 2a, b) . In three, the invasive component produced extracellular mucin in which the neoplastic cells were suspended, similar to colloid carcinoma (Fig. 2c, d ).
IPMNs (n = 22)
Of the 22 cases of IPMN selected for immunophenotype comparison, 7 were gastric type, 8 were intestinal-type IPMNs, and 7 were pancreatobiliary-type IPMNs. All gastric-type IPMNs had low-grade dysplasia, and all intestinal-type and pancreatobiliary-type IPMNs had high-grade dysplasia [42] . Eight of the IPMNs were associated with an invasive carcinoma, five of which were microinvasive. Two others were more widespread colloid carcinoma, and one was widespread tubular carcinoma. Vascular invasion and lymph node metastases were seen in two cases.
Immunohistochemical findings
The results of the immunohistochemical labeling are summarized in Tables 3 and 4 .
Markers associated with genetic alterations previously described in DAs and IPMNs p53, mesothelin (Fig. 3) , and claudin-4 expressions were seen only in architecturally complex areas of IOPNs and highgrade dysplastic areas of IPMNs. A higher proportion of IOPNs labeled with antibodies to mesothelin [21/24 (87.5 %) of IOPNs vs 6/22 (27 %) of 
Mucin proteins and differentiation markers
All IOPNs (100 %) and the vast majority (21/22, 95 %) of IPMNs were reactive for MUC5AC. MUC1 labeling (Fig. 4 (Tables 3 and 4 ). All cases that expressed claudin-4 ( Fig. 5b ) also immunolabeled for MUC2. MUC6 was expressed fairly consistently in the cystic areas with pyloric gland-like appearance as well as in the basal aspects of the papillary regions of both IOPNs and IPMNs. However, the expression in the papillary regions was different. The vast majority of IOPNs (8/9, 89 %) revealed MUC6 expression (Fig. 6 ), but only 6/21 (29 %) IPMNs revealed MUC6 expression (p = 0.002) in their papillae, and the degree of expression was much stronger in IOPNs compared to IPMNs. Of note, all of the MUC6-positive papillae were pancreatobiliary type. No significant MUC6 immunolabeling was noted in gastric-type or intestinal-type papillae as we previously reported [18] . CDX2 expression (Fig. 5c ) was seen predominantly in intestinal-type IPMNs (7/8, 88 %), with all cases coexpressing MUC2 (Fig. 5a) . A minority (2/22, 9 %) of IOPNs expressed CDX2, in areas with goblet cells, which also labeled with MUC2 (Fig. 5a) 
Discussion
In the current (2010) WHO classification [2] , IOPNs have been grouped together with IPMNs because they share features such as intraductal papillary growth, cyst formation, and a more indolent course than pancreatic DAs in situations with and without an invasive component [1, 3, 4, 43, 44] . However, IOPNs are distinguished from IPMNs by the morphologic appearance of the epithelium lining the papillae. IPMNs are composed of mucinous columnar epithelium, while IOPNs are composed of large cells with finely granular, eosinophilic IOPN intraductal oncocytic papillary neoplasm, IPMN intraductal papillary mucinous neoplasm a There was diffuse/strong expression in IOPNs and consistent but much weaker expression in pancreatobiliary-type IPMNs b Seen in goblet cells Fig. 4 Half of intraductal oncocytic papillary neoplasms expressed MUC1, especially in architecturally complex areas (×100) Fig. 3 The majority (87.5 %) of intraductal oncocytic papillary neoplasms labeled strongly with antibody against to mesothelin (×200)
cytoplasm. This oncocytic appearance is due to the presence of abundant mitochondria, as can be demonstrated by electron microscopy [1] . Recently, studies of genetic alterations and mucin profiles have helped to characterize the intraductal neoplasms of the pancreas in detail [9, 10, 13, 15, 22, 27, [45] [46] [47] and also have shown that intestinal-type IPMNs have differences in genetic progression patterns compared to DA [12, 20-22, 25-27, 29, 48] . Several other studies have investigated the patterns of mucin protein expression and genetic alterations in IOPNs [10, 14, 37] , including our study analyzing a series of IOPNs by targeted next-generation sequencing [40] , and have shown that IOPNs are genetically distinct from IPMNs. However, to the best of our knowledge, this the first study comparing immunohistochemical profiles of IOPNs and IPMN using a large spectrum of antibodies associated with genetic alterations previously described for DAs and IPMNs as well as antibodies to mucins and differentiation markers.
Our results showed that there are differences between IOPNs and IPMNs in mesothelin and claudin-4 expression (Figs. 3 and 5): Mesothelin is a glycoprotein of unknown function that has been shown to be overexpressed in DA, by serial analysis of gene expression and immunohistochemistry [49] [50] [51] , and in invasive carcinomas arising from IPMNs, by cDNA microarray analysis [48] . Similarly, in our study, mesothelin labeling was mostly observed in cases with highgrade dysplasia and associated invasive carcinoma in both tumor types. However, a higher proportion of IOPNs labeled with mesothelin (87.5 vs 27 %, p < 0.001). Even among only the high-grade precursors, mesothelin was expressed more than twice as commonly in IOPNs as in IPMNs (91 vs 40 %, p < 0.001). Claudin-4 encodes for a transmembrane protein known to function as a high-affinity receptor for Clostridium perfringens enterotoxin that is concentrated in tight junctions of the liver and kidney [52] . It has been shown to be overexpressed in DAs and in invasive carcinomas arising from IPMNs [14, 48, 51, [53] [54] [55] . In our study, 41 % of IPMNs and only 9 % of IOPNs expressed claudin-4 (p = 0.01). Interestingly, in all positive cases, the areas of neoplasm that expressed claudin-4 also expressed MUC2 (and in some, CDX2, see below), a marker of intestinal differentiation [56] (Fig. 5) . Since specific roles of mesothelin and claudin-4 in oncogenesis and cellular differentiation are unknown, it is difficult to speculate about the reason for these differences between IPMNs and IOPNs. However, the high rate of mesothelin expression in IOPNs suggests that it may have some potential as a biomarker for this entity.
In contrast to mesothelin and claudin-4 expression, IOPNs and IPMNs appear to have similar changes in SMAD4, β-catenin, and p53 protein expression: None of the cases of IOPN or IPMN showed loss of expression of SMAD4, consistent with most prior studies suggesting that SMAD4 is not altered in IPMNs [29, 37] . Only one case of IOPN and two cases of pancreatobiliary-type IPMN showed focal abnormal nuclear reactivity for β-catenin. Alterations in the adenomatous polyposis coli (APC)/β-catenin pathway have been reported in non-ductal pancreatic lesions such as acinar cell carcinoma, solid pseudopapillary neoplasm, and pancreatoblastoma but are only rarely found in DA [57, 58] . Although some reported IOPNs have had focal acinar differentiation based on immunolabeling for pancreatic enzymes (trypsin or chymotrypsin), there is no evidence that IOPNs are related to acinar neoplasms at the genetic level [1, 40] .
Only three IOPNs had nuclear reactivity for the p53 protein in approximately 10 % of the neoplastic cells. Two cases of intestinal-type IPMN and four cases of pancreatobiliary-type IPMN with high-grade dysplasia also showed nuclear labeling in more than 50 % of the neoplastic cells. In previous studies, TP53 gene mutations have been identified in 0-38 % (weighted mean, 21 %) of IPMNs, with most cases showing mutation only in highgrade dysplasia and invasive carcinoma [20, 25, 26] . In pancreatic DA and PanIN, abnormalities in p53 expression are detected more often in invasive carcinomas (60 %) and PanIN3 and rarely in lower grade lesions [28] . Our results in combination with previous studies suggest that TP53 gene may not be inactivated in IOPNs [40] . Also, its inactivation appears to be less common in IPMNs than in DA and is a late event in genetic progression.
MUCs are glycoproteins with various roles in homeostasis and carcinogenesis. MUC1 may promote carcinogenesis by suppressing cell-cell and cell-matrix interactions, and its expression has been associated with increased metastatic ability of pancreatic cancer cell lines [59] . MUC2 is strongly expressed by goblet cells of the human gastrointestinal tract, and it produces a secretory mucus gel that protects the epithelium [60] . MUC5AC is a gastric-type secretory mucin and is expressed in the foveolar cells of gastric mucosa [9] . The expression of these three mucin types in pancreatic DAs, IPMNs, and PanINs has been extensively studied [8-11, 14, 15, 18, 46, 61, 62] . MUC5AC immunolabeling has been seen in some DAs and in a high percentage of IPMNs (13 vs 83 %) [9] . Expression of MUC1 is seen more in IPMNs with high-grade dysplasia and an invasive component (especially those of the pancreatobiliary-type differentiation), high-grade PanINs, and invasive DAs [8, 10, 11, 14, 46, 61] . MUC2 expression is seen in IPMNs with intestinaltype papillae and in invasive colloid carcinomas associated with these IPMNs [10, 11, 14, 15, 46] . DAs are consistently negative for MUC2 [8, 9] . Thus, MUC1 is seen as a marker of an aggressive phenotype, while MUC2 is seen as a suppressor of growth and is associated with a more indolent pathway in pancreatic carcinogenesis [11] .
Studies of MUC1 and MUC2 expression in IOPNs have been less extensive, with one showing expression of both [10] and another showing lack of MUC2 [14] . In the current study, we found that IOPNs and IPMNs both expressed MUC1 and MUC2, but in different proportions depending on grade and type of papillae. The rate of MUC1 and MUC2 positivity in IPMNs was 27 and 45 %, respectively, similar to previous results [8, 11, 15, 46, 61] . Also, in accordance with previous findings was a high proportion of MUC2 positivity in intestinal-type IPMN vs than in pancreatobiliary-type IPMN or gastric-type IPMN. The unexpected finding was that a high percentage (52 %) of IOPNs labeled with antibodies to MUC1 (Fig. 4) . Similarly, we identified diffuse and strong MUC6 expression in the vast majority (89 %) of IOPNs. IPMNs with pancreatobiliary-type papillae also consistently (100 %) expressed MUC6, even though the degree of expression was less intense than in the IOPN. In contrast, there was no significant MUC6 labeling in other types of papillae. Thus, despite the clinically indolent nature of IOPNs, the mucin profile is similar to that seen in the more aggressive subtype of IPMN, i.e., pancreatobiliary-type IPMN.
HepPar-1 is a mouse monoclonal antibody that reacts with a poorly characterized antigen present in hepatocytes, probably within mitochondria [63] . However, studies have also shown that HepPar-1 can be expressed in carcinomas from the pancreatobiliary tree, the tubular gastrointestinal tract, lung, and genitourinary tract [64] . Like hepatocytes, the epithelium of IOPNs has an oncocytic and granular appearance and abundant mitochondria [1] . We found that 61 % of IOPNs were HepPar-1 reactive. A prior study on hepatic IOPNs has also reported HepPar-1 labeling [65] . This result may provide more support for the hypothesis that the epitope for HepPar-1 is within mitochondria. However, 38 % of intestinal-type IPMNs and 14 % of pancreatobiliary-type IPMNs, which all lacked oncocytic cytology, also focally labeled for HepPar-1. Furthermore, we have found no expression in oncocytic neoplasms of other organs such as the kidney, thyroid, and salivary glands (Laura Tang, MD, PhD and David S Klimstra, MD; personal communication 2005). Without knowing the specific epitope that this antibody reacts to, it is difficult to explain the reason or the significance of this immunolabeling in IOPNs and IPMNs, but we do not believe that there is true hepatocellular differentiation in these neoplasms. In support of this assertion, we have previously reported that in situ hybridization for albumin mRNA, known as one of the most specific measures of hepatocellular differentiation, is negative in hepatic IOPNs [65] .
In summary, although its intraductal nature and somewhat overlapping clinicopathologic features have led to classification of IOPN as a variant of IPMN, the results of this study suggest that the differentiation pathway of IOPNs differs from those of IPMNs and DAs, supporting recent genetic analyses [14, 22, 33, [37] [38] [39] [40] . The exact molecular mechanism behind the origin and progression of IOPNs remains to be elucidated and will offer additional insight into its pathogenesis.
